Share on LinkedInShare on LinkedIn

ARTICLE · 24 AUGUST 2012

More On Myriad - "Gene Patenting" Debate Continues

As promised in my earlier post, today our firm issued its review of the much anticipated decision regarding the "gene patenting" case (formally known as The Association For Molecular Pathology. et al. v. USPTO et al.)

United StatesIntellectual Property

As promised in my earlier post, today our firm issued its review of the much anticipated decision regarding the "gene patenting" case (formally known as The Association For Molecular Pathology. et al. v. USPTO et al.) The case was before the Federal Circuit on remand from the U.S. Supreme Court's March 20, 2012 decision in Mayo Collaborative Services v. Prometheus, Inc. The same three-judge panel heard the case on remand, and the judges reached essentially the same results on the interpretation of  the patent-eligibility of claims under 35 USC § 101 as their earlier decision on the issues. Judge Lourie wrote the opinion for the court, Judge Moore concurred in the result, and Judge Bryson concurred in part and dissented in part. Read Foley & Lardner's review and analysis here and Courtenay Brinckerhoff's PharmaPatents post.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from